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Abstract
The skin clinical phenotypes of nonsteroidal anti-inflammatory drug (NSAID) 
hypersensitivity (NH) are very heterogeneous with several syndromes after NSAID 
intake, which include different symptoms, different organ involvement and different 
associated concomitant diseases and possibly different underlying pathophysiology 
and mechanisms. Making a correct diagnosis in NH is an exciting journey for any 
allergist. Thus, to classify these diseases properly will be pivotal for appropriate diag-
nostic and management strategy. Treatment modalities are depending on the clinical 
phenotypes of NH and they will embrace for each patient: the avoidance of culprit 
NSAID, the finding of well-tolerated NSAID and in certain cases, desensitization 
procedures when the NSAID treatment was absolutely needed as well as the control 
of associated diseases such as spontaneous chronic urticarial or allergic respiratory 
diseases. This review updates the recent evidence of classification, diagnostic strate-
gies, and management of skin NSAID hypersensitivity reactions.
Keywords: NSAID hypersensitivity, urticaria, angioedema, single-blind  
placebo-controlled oral challenge, management
1. Introduction
Nonsteroidal anti-inflammatory drugs (NSAID) are one of the most commonly 
used drugs worldwide. NSAIDs are a major cause of hypersensitivity reactions, 
and they suppose up to half the cases of adverse reactions evaluated in a tertiary 
allergy unit [1]. Adverse reactions to NSAIDs account for 12% to 29.6% of all 
adverse reactions in hospital admissions. Most adverse reactions to NSAIDs belong 
to type A, which are dose-dependent and predictable from their pharmacological 
actions. Common type A reactions include gastrointestinal bleeding and acute 
kidney injury. Type B reactions, also known as NSAID hypersensitivity (NH) reac-
tions, account for 8.4% to 18.3% of total adverse reactions to NSAID [2]. NSAIDs 
are a large and chemically heterogeneous group of drugs that inhibit the enzyme 
cyclooxygenase (COX) 1 and 2 isoforms, an so block the production of prostaglan-
dins from arachidonic acid.
NSAIDs are typically divided into groups based on their chemical structure and 
selectivity for blocking COX-2: acetylated salicylates (aspirin), non-acetylated salic-
ylates (diflunisal, salsalate), propionic acids (naproxen, ibuprofen, dexketoprofen), 
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acetic acids (diclofenac, indomethacin, aceclofenac, tolmetin), enolic acids (meloxi-
cam, piroxicam), anthranilic acids (meclofenamate, mefenamic acid, niflumic 
acid), naphthylalanine (nabumetone), pyrazolones (metamizole, propyfenazone) 
and selective COX-2 inhibitors (celecoxib, etoricoxib).
Several distinct clinical syndromes are described regarding NH, most often 
manifested as respiratory reactions (e.g, bronchospasm and nasoocular reaction), 
urticaria/angioedema or systemic anaphylaxis. NH often appears in patients who 
also suffer certain concomitant diseases, such as chronic rhinosinusitis with nasal 
polyps and bronchial asthma or spontaneous chronic urticaria. Both, the type of 
reaction after NSAID exposure and the concomitant associated disease are criti-
cal to classify the NH [3]. The focus of this chapter will provide an overview on 
all the aspects of skin NSAID hypersensitivity immediate reactions, from clinical 
symptoms to leading practical recommendations with respect to diagnosis and 
management.
2.  A working classification of skin NSAID hypersensitivity based on 
clinical phenotypes
Controlled oral challenge is the only definitive way to diagnose the reactions 
caused by NSAIDs. These challenge-proven immediate responses are a wide group 
of disorders that includes respiratory, cutaneous and anaphylaxis reactions [1, 3].
The mechanisms of NH are unknown, but two general hypotheses have been 
proposed [4]. The first one, an enzymatic activity inhibition of at least the cyclo-
oxygenase-1 (COX-1) isoform that may inhibit the prostaglandin synthesis and thus 
deregulate the 5-lipooxygenase pathway, with cys-leukotriene hyperproduction 
in some susceptible patients. All NSAIDs that inhibit the COX-1 isoform could 
precipitate the reaction. For this reason, cross-reactivity among COX-1 inhibitor 
NSAIDs can be demonstrated in all patients with respiratory reactions and in most 
patients with urticaria/angioedema reactions (multiple reactors) [1, 3, 4]. The 
second mechanism can be applied only to a small subset of patients with NSAID 
hypersensitivity, as those with systemic anaphylaxis [4]. We have previously dem-
onstrated that patients with NSAIDs-induced systemic anaphylaxis can react only to 
one specific NSAIDs and tolerate other COX-1 inhibitor NSAIDs in controlled oral 
challenges. Up to 1/3 of patients with NSAID induced systemic anaphylaxis might 
present immediate acute urticarial previous to anaphylactic episode when taken a 
specific NSAID (selective reactors) [3–5].
At least, three subsets of these patients with NH may have an associated under-
lying disease: in fact, around 10 percent of patients with chronic rhinosinusitis with 
nasal polyps and moderate-to-severe asthma and 30 percent of those with chronic 
urticaria/angioedema may present a nasoocular/asthmatic or urticarial reaction 
after NSAID exposure at some times in their lives, respectively [6]. Some clinical 
phenotypes of skin NSAID hypersensitivity are also definitely associated with 
allergic respiratory disease [3, 7].
Therefore, the diagnostic approach determines very different clusters of patients 
[3, 8]. Those who present clinical reactivity between different NSAIDs (multiple 
reactors) versus those who develop a reaction exclusively to a specific NSAID (selec-
tive reactors), and secondly, those in whom there is a very defined concomitant 
associated disease from the clinical and biological point of view. NSAID exposure 
exacerbates these diseases, determining a clinical reaction. However, the NSAID 
withdrawal does not determine a notable modification of the natural history of 
the disease, which often must continue to be treated despite the avoidance of 
NSAID [8].
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Therefore, the NSAID reaction is an epiphenomenon that together with other 
clinical features constitutes what we have called the clinical phenotype (formerly 
called the NSAID-reaction complex) [1, 3]. This classification based on clinical 
phenotypes is a real and practical approach in the daily clinic, which will allow us to 
make the best appropriate diagnostic and therapeutic decisions.
3. The skin clinical phenotypes of NSAID hypersensitivity
The skin reactions are the most prevalent clinical phenotypes in patients 
with NSAID hypersensitivity. We have described at least 5 clinical phenotypes of 
immediate-type of skin NSAID hypersensitivity: [3, 7] NSAID-exacerbated cutane-
ous disease (NECD), NSAID-induced urticaria/angioedema (NIUA), two clinical 
phenotypes (NSAID induced isolated periorbital angioedema and NSAID induced 
recall urticarial) which are present exclusively in patients with respiratory allergy, 
mainly house dust mites; and a single NSAID induced urticaria/angioedema/
anaphylaxis (SNIUAA) (Table 1). The last mentioned is probably an IgE-mediated 
allergy. The remaining phenotypes do not have an immunological pathophysiology, 
but are caused by inhibiting COX-1 resulting in an imbalance in eicosanoid media-
tors, as above outlined.
3.1 The NSAID-exacerbated cutaneous disease
Patients with NECD suffer from spontaneous chronic urticaria and/or angio-
edema (CSU) and experience a worsening of these symptoms after NSAID intake. 
Most reactions appear between 1 to 12 hours after administering NSAID and last 
several days until the reaction is controlled with supplemental doses of antihis-
tamines and/or corticosteroids. In up to 30 percent of cases facial, neck and hand 
angioedema may occur during the clinical exacerbation; an isolated angioedema 
is rarely a possible manifestation of NECD. Approximately 30% of patients with 
chronic spontaneous urticaria present exacerbations of their disease after NSAID 
exposure throughout their lives [1, 3–5, 8]. A positive correlation between the basal 
CSU activity disease and the possibility of a NSAID challenge reaction have been 
described in NECD patients [8].
NSAID reactivity 
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Skin clinical phenotypes of NSAID hypersensitivity.
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Since CSU is often a self-limiting disease within months to years, NECD can 
potentially remit with the resolution of CSU. However, NECD patients seem to have 
a distinct phenotype compared with NSAID-tolerant CSU patients: the latter have 
a shorter duration of CSU and less often have angioedema when compared with 
NECD patients [9].
3.2 NSAID-induced urticaria/angioedema
Patients with NSAID-induced urticaria and/or angioedema (NIUA) do not have 
spontaneous urticaria and/or angioedema, but only the reactions develop after the 
NSAID intake. NIUA is a multiple NSAID hypersensitivity syndrome and there is 
cross-reactivity between chemically unrelated NSAIDs. Since patients often start 
to avoid NSAIDs after their first reaction, this cross-reactivity might not always be 
clear. Patients can report isolated urticaria, angioedema or a combination of both. 
A small proportion of patients with NIUA developed chronic spontaneous urticaria 
after 10 year- period of follow-up [10]. So, there is a certain degree of interrelation-
ship between both phenotypes, NECD and NIUA, and possibly in some patients 
they represent different stages of the same disease.
All patients with NECD and NIUA show a pattern of multiple reactivity between 
NSAID, dependent on the level of in vitro inhibition potency of COX −1 isoform 
(Table 2).
3.3 Isolated periorbital angioedema (iPA), or the infanto-juvenile form of NH
This type of reaction usually affects children and young people, with an onset 
in the first or second decade of life in more than 80% of cases and, in all cases, an 
associated respiratory allergy is detected, mostly caused by mites, suggesting a close 
relationship with aspirin exacerbated respiratory disease (AERD) with which they 
share not only the concomitant disease, but also the pattern of multiple reactivity 
among NSAID [3, 6].
Category Drug Doses
Placebo Lactose
Highly selective COX-2 inhibitor Celecoxib 50, 100, 200 a
Etoricoxib 30, 60 a
Preferential COX-2 inhibitor Meloxicam 7.5, 15 mg a
Weak, non-discriminatory COX-1/COX-2 
inhibitor
Paracetamol 100, 250, 500, 1000 mg a
Potent, non-discriminatory COX-1/COX-2 
inhibitor
Diclofenac 25, 50 mg b
Ibuprofen 50, 150, 250, 600 mg a, d
Metamizole 10, 50, 125, 250, 575 mg 
a, e
Acetylsalycilic acid 50, 100, 250, 500 mg c, f
Drugs were administered in an opaque capsule at the following intervals between each dose: a60 minutes, b120 
minutes and c180 minutes. dThree doses, efour doses or ftwo doses were administered on the first day, and d, eone dose 
or ftwo other doses on the second day.
Table 2. 
NSAIDs and doses used for single-blind, placebo controlled oral challenge.
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Within this group of patients and in close relationship with the atopic phe-
nomenon, a new syndrome has been described: the systemic anaphylaxis triggered 
by ingestion of food contaminated by mites (NSAIDs sensitivity mite-ingestion 
reaction syndrome or also recently called oral mite anaphylaxis) [11, 12]. Most of 
the patients presented common clinical characteristics: they had respiratory allergy 
to mites, presented mostly periorbital angioedema and presented anaphylactic 
episodes of variable severity in relation to the ingestion of food made with cereal 
flour (wheat, oat and corn), without any evidence of food allergy during the clini-
cal study. 87% of the study group presented intolerance to aspirin, contrasting with 
the frequency of less than 2% that we observed in the population of patients allergic 
to domestic dust mites. This meant that an atopic aspirin intolerant was up to 300 
times more likely to suffer a severe reaction from ingestion of mites than a tolerant 
patient. Microscopic analysis of the flour revealed extreme contamination of the 
flour by Dermatophagoides farinae and other mites of the Acaridae family (specifi-
cally Tyreophagus entomophagus and Suidasia medinensis). At present, the cause of 
the association of aspirin intolerance with systemic reactions by ingestion of food 
contaminated by mites is unknown.
3.4 NSAID-induced recall urticaria
Recall urticaria (RU) is a rare biologic phenomenon characterized by the exis-
tence of hives only in the previously injected site when the patient is exposed again 
from another source. The most common example are patients who have received 
previously subcutaneous allergen immunotherapy (sq AIT) and present focal skin 
reaction at the sites of previous allergens injection when a new kind of allergen shot 
was administered or after heavy ambiental exposure to the allergen [13].
We recently described a patient with allergic respiratory disease who underwent 
sq. AIT to house dust mites after a 5 year-period. Two years after allergen immu-
notherapy discontinuation, patient first experienced an immediate local urticarial 
reaction with multiple hives at previous sq. AIT injection sites after metamizole and 
ibuprofen intake. SBPCOC with ibuprofen and aspirin was performed and elicited 
multiples hives in a circumscribed area in both arms, although a controlled chal-
lenge with celecoxib was negative.
In our patient, the symptoms were elicited by different NSAIDs (Ibuprofen, 
metamizol and aspirin) which resembles the pattern of patients with skin cross-
reactive phenotypes of NSAID hypersensitivity. This suggests that the enzymatic 
inhibition of COX type I isoform could play a role in the development of this 
specific reaction. The tolerance of highly selective COX type 2 inhibitors such as 
celecoxib in our patient reinforces this hypothesis. However, the nature of the 
relationship between COX-1 inhibition and the local immunological trace of mite 
remains largely unknown. This phenomenon might be a new phenotype of skin 
NSAID hypersensitivity which would appear in those patients with respiratory 
allergy treated with sq. AIT [7].
3.5 Selective acute urticaria/angioedema and anaphylaxis
The existence of underlying diseases is common in NECD, NIUA and IPA. 
However, there is another phenotype of otherwise healthy patients, (i.e. without 
any concomitant disease associated) who experience immediate reactions of urti-
carial or anaphylactic type after the administration of a specific NSAID [1, 3–5, 8].
Up to 15% of patients with NSAID-induced urticaria present a selective pattern 
of sensitivity to NSAIDs, [8] with a predominance of certain NSAID groups, such as 
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those derived from the pyrazole group (metamizole) followed in order of frequency 
by ibuprofen, diclofenac and paracetamol, A selective pattern involves SBPCOC 
tolerance to other NSAIDs not involved in the clinical reaction, including those that 
are potent inhibitors of COX isoform 1.
Immediate systemic reactions present clinical and biological features that are 
compatible with a possible immunological mechanism: they are generally anaphy-
lactic, selective and, on certain occasions, can be associated with positive skin tests 
that can be read immediately (such as metamizole) [14].
Recently, Doña et el have described some patients who may develop immediate 
reactions to several NSAIDs but tolerate ASA (the NSAIDs-multiple selective imme-
diate reaction phenotype). Patients usually present with a biselective or triselective 
pattern: they presented different episodes of anaphylaxis to ibuprofen and diclof-
enac while tolerate an aspirin challenge or developing hypersensitivity reactions to 
three non chemically related NSAIDs [1].
Although the selective form is the most frequent clinical form of NSAID anaphy-
laxis (96%), a small subgroup of patients with phenotypes associated with multiple 
reactivity can present an anaphylactic reaction during SBPCOC. Patients with NIUA 
and exceptionally periorbital angioedema may present with a systemic reaction 
after administration of a potent COX-1 inhibitor NSAID. In rare cases, the systemic 
reaction may be a clinical phenotype in itself, with patients exhibiting this clinical 
response to any exposure to NSAID [3].
4. Diagnostic strategy in skin reactions to NSAID
The main tools that allow us to deal with cutaneous reactions to NSAIDs  
are the clinical history and controlled re-exposure to NSAIDs in a hospital setting 
[3]. The careful and complete review of clinical reactions to NSAID is essential 
before any challenge procedure and allows us to provisionally classify the patient 
with NH, while the latter, the SBPCOC, definitively assigns the patient to a spe-
cific phenotype. Our objective is to offer the best analgesic, anti-inflammatory or 
antiplatelet alternatives in the event that the patient tolerates the NSAID without 
reaction.
4.1 To classify, to classify, to classify…always
The clinical history is the basic method of temporarily assigning the patient to 
a specific clinical phenotype. The phenotypic classification of any patient with a 
possible NH (Table 1) will be the first (and the most important) diagnostic step in 
the investigation of these types of reactions. Properly classifying NH will help us to 
choose safest diagnostic approach for each patient [1, 3–5, 8].
The first key element to classify these patients will be the time elapsed between 
the administration of NSAID and the beginning of the reaction. The so-called 
latency time allow us to differentiate the reactions in: immediate (less than 
24 hours, usually between 1 and 2 hours) and delayed reactions (over 24 hours). 
Secondly, we will have to evaluate the clinical manifestations of the reaction (respi-
ratory, cutaneous or systemic), the NSAID involved, the route of administration 
and the reason why the drug was prescribed, as well as the coexistence of associated 
concomitant diseases (chronic rhinosinusitis with nasosinusal polyposis, bronchial 
asthma, spontaneous chronic urticaria or allergic respiratory disease). Thirdly, we 
will have to determine the NSAID tolerated previously and after the reaction. This 
will allow us to make a first historical approach to NSAID reactivity status: multiple 
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reactor with reactivity among non-chemically related NSAIDs (Table 3) or selec-
tive reactor with sensitivity to a single NSAID with tolerance to at least one potent 
COX-1 inhibitor NSAID (Table 4).
Therefore, the classification of patients based on clinical phenotypes is critical in 
addressing diagnostic and therapeutic strategies in these patients. The identification 
of comorbidities such as chronic spontaneous urticaria, allergic respiratory disease 
or reactions to mite-contaminated cereal flour-based foods are key clinical elements 
that might define a phenotype and predict in most cases multiple reactivity to 
different groups of NSAIDs. The worsening of spontaneous chronic urticaria after 
NSAID administration and the development of the reaction within 1 to 6 hours of 
NSAID administration are common clinical features that can be referred up in most 
patients with skin-type reactions.
In a percentage of cases, clinical information on reactivity status is limited, 
either because the patient has had only a single reaction with a single NSAID or 
because of the impossibility of determining each of the NSAIDs involved in the 
patient’s lifetime reactions. In these cases, determining this status is essential to 
approach a therapeutic plan. The only way to determine the reactivity status is 
through SBPCDC with NSAIDs that have differential inhibition against each of 
isoforms COX-1 and COX-2. However, we could collect in the clinical history some 
findings that may allow us to identify a multiple or selective reactor status (Tables 3 
and 4). In general, a NSAID highly selective for COX-2 inhibition, such as a COXIb, 
will be better tolerated than a potent COX 1–2 inhibitor in patients who are multiple 
reactors. The degree of COX inhibition is directly proportional to the probability 
of reaction and the intensity of its clinical manifestations [1, 3–5, 8]. In the case 
of a selective reactor, all COX-1 inhibitor NSAIDs will be tolerated, except the one 
involved in the historical reaction (or those which are chemically related).
• Urticaria/angioedema which appear between 1 to 6 hours to NSAID intake
• Bilateral periorbital angioedema after NSAID intake in children
• Nasoocular and/or asthmatic reaction after NSAID intake
• Historical reactions to other non-chemically related NSAID
• Chronic rhinosinusitis with nasal polyps
• Moderate-to-severe bronchial asthma
• Spontaneous chronic urticaria
• Inducible (dermographism, cholinergic) chronic urticaria
• Allergic respiratory disease to house dust mites
• Systemic reaction after flour-based food ingestion
Table 3. 
Clinical findings suggesting a NSAID multiple reactor.
• Urticaria which appear within 1 h to NSAID intake
• Inmediate Systemic anaphylaxis after NSAID administration
• Historical tolerance to other non-chemically potent COX-1 inhibitor NSAID
• No concomitant associated diseases
Table 4. 
Clinical findings suggesting a selective reactor status.
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4.2  Principles to design the best controlled oral challenge for each clinical 
phenotype
The fundamental objectives of SBPCOC is threefold: first, to determine the 
clinical syndrome associated with the reaction after administration of the NSAID. 
In the case of systemic anaphylaxis due to an NSAID, the use of the NSAID involved 
during the clinical reaction is completely contraindicated. Second, determine the 
tolerance pattern to NSAIDs in an individual patient. A negative SBPCOC will 
determine the NSAID reintroduction of the treatment in the patient with NH. The 
stratification of NSAID according to their inhibitory potency of each of the COX1 
and COX2 isoenzymes determines the likelihood of reaction and therefore the order 
of administration of NSAIDs during SBPCOC [15]. Thus, for example, in a patient 
with diclofenac and ibuprofen-induced NIUA, a SBPCOC with celecoxib or etori-
coxib is highly likely to be tolerated (and therefore included in the self-care plan 
for patient management) while an SBPCOC with another strong COX-1 inhibitor 
NSAID is highly likely to induce a reaction, diagnose the patient, and determine a 
multiple pattern of reactivity. And third and finally, it allows us to initiate a desen-
sitization procedure in patients with immediate respiratory or cutaneous reactions 
requiring a desensitization procedure that determines the introduction of an NSAID 
for anti-inflammatory or antiaggregant treatment if necessary. Desensitization is a 
procedure which will be discussed later and which determines a temporary state of 
tolerance while the administration of the NSAID persists.
4.2.1 SBPCOC with NSAID in patients with cross-reactive skin reactions
The approach to patients with the various phenotypes of cross-reactive skin 
reactions (NECD, NIUA, IPA and NIRU) is very similar. We always have to bear 
in mind that these patients seek our advice because they lack analgesic and anti-
inflammatory alternative strategy, and their fundamental objective is to find an 
alternative that will solve their underlying disease without inducing a reaction. 
Therefore, the stratification of SBPCOC with NSAIDs plays an essential role in these 
cases, since it is directly related to a potential positive response during the challenge 
[15]. In virtually all cases these patients tolerate COXiB. Even in the rare cases where 
they do not tolerate a given COXiB, it is essential to expose them to another COXiB 
as it can be otherwise tolerated [16].
NSAIDs, which are COX2 inhibitors, but which inhibit COX-1 in a dose-dependent 
manner, such as meloxicam, would be the next alternative to propose in these 
patients. Paracetamol, a weak COX-1 and COX-2 inhibitor, is generally tolerated at the 
time of the clinical history by most patients. Its analgesic potential, but the absence 
of anti-inflammatory effects, is what finally decides the patient to go to the allergist 
looking for more appropriate alternatives. The use of potent COX1 and COX2 inhibi-
tors, such as aspirin, ibuprofen, metamizole or diclofenac necessarily determine a 
reaction and therefore a diagnosis in this type of reaction [3, 8, 15].
4.2.2 SBPCOC with NSAID in patients with selective urticaria and anaphylaxis
The existence of an NSAID-induced anaphylaxis predicts the existence of a 
selective pattern that in many cases can already be detected in the clinical history, 
because the patient has tolerance to other non-chemically related NSAIDs. In a study 
of patients with NSAID anaphylaxis we have demonstrated that patients tolerated 
with impunity any NSAID, if we avoided the historically implicated NSAID or 
other chemically related NSAIDs during the SBPC [3]. In the group of patients with 
pyrazolone (metamizole, propyfenazone) anaphylaxis in Spain, skin tests (prick 
9
Clinical Phenotypes in NSAID-Induced Urticaria/Angioedema
DOI: http://dx.doi.org/10.5772/intechopen.96718
test at 400 mg/mL and ID at 4 mg/mL) are extremely useful tools to detect an IgE-
mediated allergy to these drugs. A positive metamizole skin test will always deter-
mine a safe SBPCDC if another non-pyrazolone NSAID is used during challenge. 
With other NSAIDs, in my experience, skin tests have extremely low sensitivity.
4.2.3 Treating reactions during SBPCOC
NSAID challenges always pose a certain risk, depending on the phenotype of the 
patient. Therefore, these challenges should be performed by experienced special-
ized nurses and allergists with the appropriate resources and access to emergency 
medical and intensive care.
4.3  The single-blind, placebo controlled oral challenge with NSAID: how do we 
do it?
The SBPCOC with NSAID is the gold standard for the diagnosis of skin NH. 
SBPCOC is indicated in 3 main scenarios: 1) to confirm/discard if the NSAID 
involved in the reaction is responsible (especially in those cases where the history 
is not very suggestive of a reaction to NSAID); 2) To confirm/exclude multiple 
reactivity among potent COX-1 inhibitors with another NSAID, usually aspirin; and 
3) to identify potential alternative NSAIDs that are well tolerated by the patients.
However, there are several clinical situations in which it is contraindicated: If 
there is severe or uncontrolled bronchial asthma, active spontaneous urticaria/
angioedema, pregnancy, active infection, and a recent vaccination (≤ 1 week) and 
uncontrolled psychiatric disorders. Relative contraindications are also the use of 
beta-blockers or ACE-inhibitors.
We propose an order of administration of NSAIDs trying to stratify them accord-
ing to the in vitro potency of COX-1 and COX-2 inhibition (Table 2) [3, 14]. This 
risk stratification management makes us start with, some of the selective COX-2 
inhibitors (etoricoxib and celecoxib). Later, if there is no clinical response, the 
preferential COX-2 NSAIDs are continued (with a dose-dependent inhibitory effect 
on COX-1, as was the case with meloxicam). Thirdly, if there is no clinical response, 
a weak NSAID inhibiting both isoforms (e.g. paracetamol) will be administered; to 
continue, finally, with the potent COX-1 and COX-2 inhibitors.
Stratification of NSAIDs according to their COX-1 inhibition potency allows, 
to generate effective alternatives that these patients can take if the response during 
SBPCOC is negative; and to confirm the pattern of reactivity between NSAIDs that 
allows us to classify clinical phenotypes appropriately.
In the case of NECD the ideal is to carry out the study in a period of remission of 
chronic spontaneous urticaria. If this is not possible, we will titrate the treatment 
with antihistamines until the minimum effective control dose is achieved and then 
perform the SBPCOC. A complete withdrawal of all anti-histamines may determine 
a high rate of false positives in this subset of patients with NH [8].
The existence of NSAID anaphylaxis contraindicates the use of that specific 
NSAID or other structurally related one during SBPCOC [3, 8]. However, this type 
of reaction presents a selective pattern of sensitivity to NSAID, and even those with 
high COX-1 inhibition potency can be taken with impunity.
5. The management of skin NSAID hypersensitivity
The management of skin reactions to NSAIDs will aim to educate the patient 
on which drugs to avoid and to provide written therapeutic advice on which 
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alternatives to NSAIDs are potentially safe, after having tested adequate tolerance to 
them through SBPCOC.
Depending on the diagnosis and outcome of the SBPCOC, the patient can be 
advised to avoid only the culprit or all NSAID. Then, there might be a need to inves-
tigate the safety of other alternative analgesics. Selective COX-2 inhibitors are often 
a safe alternative, especially in cross-reactive patients who can tolerate acetamino-
phen. So, below 5% of patients with skin NH reacted to a selective COX-2 inhibitor. 
[17, 18] Even in those cases with a COXiB reaction, it is possible that the patient may 
tolerate other COXib without reaction and therefore an second challenge with an 
alternative COXIb must be performed [16].
Early presentations of periorbital angioedema as key features of cross-reactive 
reactions to NSAIDs in an atopic children also precluded the use of potent COX-1 
inhibitor NSAID. Paracetamol is often well tolerated in these patients. The use of a 
cyclooxygenase-2-specific medication may not be feasible in this population, and 
limits options for other medical antiinflammatory treatment. However, Loh et al. 
have recently demonstrated that etoricoxib can be used as a safe alternative in older 
children (mean age 13,5 years) with hypersensitivity to multiple antipyretics [19].
Patient with selective urticaria or systemic anaphylaxis presents a selective pat-
tern of sensitivity to NSAID, and even those with high COX-1 inhibition potency, 
but non chemically related, can be tolerated [3, 5].
Desensitization with aspirin is recommended by clinical guidelines only 
in patients with aspirin exacerbated respiratory disease and in cases of NECD 
or NIUA, in which it is strictly necessary to administer any NSAID as an anti-
aggregate, anti-inflammatory or analgesic treatment [20]. The desensitization 
procedure consists of administering progressively increasing doses of aspirin until a 
reaction is provoked which is as controllable as possible, with the aim of inducing a 
post-reaction refractory period and which we will use to reach the therapeutic dose, 
culminating the desensitization process after the administration of a dose of aspirin 
(or other NSAID) without a reaction.
Rossini et al. have published a multicenter, prospective study that demonstrates 
that a rapid standardized desensitization protocol in patients with aspirin hypersen-
sitivity undergoing coronary angiography is safe and effective, irrespective of the 
type of NH which have the patients. A low-dose aspirin could be safely continued 
without reaction in all patients throughout the next year [20].
6. Conclusions
We have clinically characterized a large population of patients with skin NSAID-
induced reactions by means of controlled oral challenges, and we have proposed a 
working classification of these clinical entities, which can be recognized through 
the distinct clinical features and the challenge results. Skin NSAID hypersensitivity 
have showed at least 5 well-defined clinical phenotypes. This classification based 
on clinical phenotypes is a real and practical approach in the daily clinic, which will 
allow us to make the best-appropriated diagnostic and therapeutic decisions.
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